Cardiac hypertrophy is a typical pathological phenotype of cardiomyopathy and a result from pathological remodelling of cardiomyocytes in humans. At present, emerging evidence demonstrated the roles of long non‐coding RNAs (lncRNAs) in regulating the pathophysiological process of cardiac hypertrophy. Herein, we would like to review the recent researches on this issue and try to analysis the potential therapeutic targets on lncRNA sites. Studies have revealed both genetic mutations related hypertrophic cardiomyopathy and the compensative cardiac hypertrophy due to pressure overload, inflammation, endocrine issues and other external stimulations, share a common molecular mechanism of ventricular hypertrophy. The emerging evidence identified the abnormal expression of lncRNAs would leading to the impairment the function of sarcomere, intracellular calcium handling and mitochondrial metabolisms. Several researches proved the therapeutic role of lncRNAs in preventing or reversing cardiac hypertrophy. With the development of delivery system for small pieces of oligonucleotide, clinicians could design gene therapy approaches to terminate the process of cardiac hypertrophy to provide better prognosis.

中文翻译：

---

心脏肥大中的LncRNA：从基础科学到临床应用。

心肌肥大是心肌病的典型病理表型，是人心肌细胞病理重塑的结果。目前，越来越多的证据表明长非编码RNA（lncRNA）在调节心脏肥大的病理生理过程中的作用。在此，我们想回顾一下有关此问题的最新研究，并尝试分析lncRNA位点上的潜在治疗靶标。研究表明，由于压力超负荷，炎症，内分泌问题和其他外部刺激，与肥厚型心肌病相关的基因突变和代偿性心肌肥大均具有共同的心室肥大分子机制。新出现的证据表明，lncRNA的异常表达会导致肌节功能受损，细胞内钙处理和线粒体代谢。多项研究证明了lncRNA在预防或逆转心肌肥大中的治疗作用。随着小片段寡核苷酸递送系统的发展，临床医生可以设计基因治疗方法来终止心脏肥大的过程，以提供更好的预后。